Home » Roche Begins Phase I Trial of Subcutaneous Formulation With Enhanze
Roche Begins Phase I Trial of Subcutaneous Formulation With Enhanze
Halozyme Therapeutics, Inc. announced that Roche has dosed the first patient in a Phase 1 pharmacokinetic clinical trial with a subcutaneous formulation using Enhanze Technology of a biologic directed to a second Roche exclusive target.
TradingMarkets
TradingMarkets
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May